Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Amsacrine
Drug ID BADD_D00137
Description Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Indications and Usage For treatment of acute myeloid leukaemia.
Marketing Status approved; investigational
ATC Code L01XX01
DrugBank ID DB00276
KEGG ID D02321
MeSH ID D000677
PubChem ID 2179
TTD Drug ID D0G9YH
NDC Product Code Not Available
UNII 00DPD30SOY
Synonyms Amsacrine | Cain's Acridine | Cain Acridine | Cains Acridine | meta-AMSA | meta AMSA | AMSA | m-AMSA | Amsidyl | SN-11841 | SN 11841 | SN11841 | NSC-156303 | NSC 156303 | NSC156303 | NSC-249992 | NSC 249992 | NSC249992 | Amsidine | Amsacrina | AMSA P-D | AMSA P D | AMSA PD | NSC-141549 | NSC 141549 | NSC141549
Chemical Information
Molecular Formula C21H19N3O3S
CAS Registry Number 51264-14-3
SMILES COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Gingivitis07.09.10.002; 11.01.04.013--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria24.07.01.047; 20.02.01.006; 21.10.01.018--
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hypersensitivity10.01.03.003--
Hyperuricaemia14.09.01.003--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypomagnesaemia14.04.02.001--
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Mood swings19.04.03.001--Not Available
Mucosal inflammation08.01.06.002--Not Available
Musculoskeletal pain15.03.04.007--
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Phlebitis24.12.03.004; 12.02.01.002--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages